Complement and the atypical hemolytic uremic syndrome in children View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-11-01

AUTHORS

Chantal Loirat, Marina Noris, Véronique Fremeaux-Bacchi

ABSTRACT

Over the past decade, atypical hemolytic uremic syndrome (aHUS) has been demonstrated to be a disorder of the regulation of the complement alternative pathway. Among approximately 200 children with the disease, reported in the literature, 50% had mutations of the complement regulatory proteins factor H, membrane cofactor protein (MCP) or factor I. Mutations in factor B and C3 have also been reported recently. In addition, 10% of children have factor H dysfunction due to anti-factor H antibodies. Early age at onset appears as characteristic of factor H and factor I mutated patients, while MCP-associated HUS is not observed before age 1 year. Low C3 level may occur in patients with factor H and factor I mutation, while C3 level is generally normal in MCP-mutated patients. Normal plasma factor H and factor I levels do not preclude the presence of a mutation in these genes. The worst prognosis is for factor H-mutated patients, as 60% die or reach end-stage renal disease (ESRD) within the first year after onset of the disease. Patients with mutations in MCP have a relapsing course, but no patient has ever reached ESRD in the first year of the disease. Half of the patients with factor I mutations have a rapid evolution to ESRD, but half recover. Early intensive plasmatherapy appears to have a beneficial effect, except in MCP-mutated patients. There is a high risk of graft loss for HUS recurrence or thrombosis in all groups except the MCP-mutated group. Recent success of liver–kidney transplantation combined with plasmatherapy opens this option for patients with mutations of factors synthesized in the liver. New therapies such as factor H concentrate or complement inhibitors offer hope for the future. More... »

PAGES

1957-1972

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00467-008-0872-4

DOI

http://dx.doi.org/10.1007/s00467-008-0872-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019980601

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18594873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement System Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Education, Medical, Continuing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemolytic-Uremic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de N\u00e9phrologie, H\u00f4pital Robert Debr\u00e9, 48 Boulevard S\u00e9rurier, 75019, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413235.2", 
          "name": [
            "Assistance Publique - H\u00f4pitaux de Paris, Universit\u00e9 Paris 7, H\u00f4pital Robert Debr\u00e9, Pediatric Nephrology, Paris, France", 
            "Service de N\u00e9phrologie, H\u00f4pital Robert Debr\u00e9, 48 Boulevard S\u00e9rurier, 75019, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Loirat", 
        "givenName": "Chantal", 
        "id": "sg:person.01274311230.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274311230.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Ranica, Italy", 
          "id": "http://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Clinical Research Center for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Ranica, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noris", 
        "givenName": "Marina", 
        "id": "sg:person.0737342403.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737342403.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges Pompidou, Biological Immunology Department, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.414093.b", 
          "name": [
            "Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges Pompidou, Biological Immunology Department, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fremeaux-Bacchi", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.0776460004.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776460004.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00467-003-1192-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013508805", 
          "https://doi.org/10.1007/s00467-003-1192-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004670100609", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038978190", 
          "https://doi.org/10.1007/s004670100609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-003-1371-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031866227", 
          "https://doi.org/10.1007/s00467-003-1371-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-007-0438-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024083847", 
          "https://doi.org/10.1007/s00467-007-0438-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-004-1526-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011641665", 
          "https://doi.org/10.1007/s00467-004-1526-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-006-0237-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048718146", 
          "https://doi.org/10.1007/s00467-006-0237-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-008-0964-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034552033", 
          "https://doi.org/10.1007/s00467-008-0964-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncpneph0465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018873317", 
          "https://doi.org/10.1038/ncpneph0465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-007-0540-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019453541", 
          "https://doi.org/10.1007/s00467-007-0540-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-11-01", 
    "datePublishedReg": "2008-11-01", 
    "description": "Over the past decade, atypical hemolytic uremic syndrome (aHUS) has been demonstrated to be a disorder of the regulation of the complement alternative pathway. Among approximately 200 children with the disease, reported in the literature, 50% had mutations of the complement regulatory proteins factor H, membrane cofactor protein (MCP) or factor I. Mutations in factor B and C3 have also been reported recently. In addition, 10% of children have factor H dysfunction due to anti-factor H antibodies. Early age at onset appears as characteristic of factor H and factor I mutated patients, while MCP-associated HUS is not observed before age 1 year. Low C3 level may occur in patients with factor H and factor I mutation, while C3 level is generally normal in MCP-mutated patients. Normal plasma factor H and factor I levels do not preclude the presence of a mutation in these genes. The worst prognosis is for factor H-mutated patients, as 60% die or reach end-stage renal disease (ESRD) within the first year after onset of the disease. Patients with mutations in MCP have a relapsing course, but no patient has ever reached ESRD in the first year of the disease. Half of the patients with factor I mutations have a rapid evolution to ESRD, but half recover. Early intensive plasmatherapy appears to have a beneficial effect, except in MCP-mutated patients. There is a high risk of graft loss for HUS recurrence or thrombosis in all groups except the MCP-mutated group. Recent success of liver\u2013kidney transplantation combined with plasmatherapy opens this option for patients with mutations of factors synthesized in the liver. New therapies such as factor H concentrate or complement inhibitors offer hope for the future.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00467-008-0872-4", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097267", 
        "issn": [
          "0931-041X", 
          "1432-198X"
        ], 
        "name": "Pediatric Nephrology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "end-stage renal disease", 
      "atypical hemolytic uremic syndrome", 
      "hemolytic uremic syndrome", 
      "factor I mutation", 
      "membrane cofactor protein", 
      "C3 levels", 
      "uremic syndrome", 
      "factor H", 
      "anti-factor H antibodies", 
      "liver-kidney transplantation", 
      "low C3 levels", 
      "factor I levels", 
      "factor H dysfunction", 
      "age 1 year", 
      "complement alternative pathway", 
      "first year", 
      "HUS recurrence", 
      "graft loss", 
      "relapsing course", 
      "renal disease", 
      "worse prognosis", 
      "I mutations", 
      "I levels", 
      "high risk", 
      "complement regulatory protein factor H", 
      "new therapies", 
      "H antibodies", 
      "patients", 
      "regulatory protein factor H", 
      "complement inhibitors", 
      "factor I", 
      "beneficial effects", 
      "disease", 
      "plasmatherapy", 
      "syndrome", 
      "early age", 
      "children", 
      "cofactor protein", 
      "factor B", 
      "onset", 
      "mutations", 
      "alternative pathway", 
      "years", 
      "thrombosis", 
      "prognosis", 
      "transplantation", 
      "recurrence", 
      "group", 
      "dysfunction", 
      "therapy", 
      "levels", 
      "liver", 
      "antibodies", 
      "disorders", 
      "age", 
      "HUS", 
      "risk", 
      "I. Mutations", 
      "inhibitors", 
      "past decade", 
      "options", 
      "pathway", 
      "C3", 
      "course", 
      "factors", 
      "half", 
      "recent success", 
      "protein", 
      "genes", 
      "regulation", 
      "complement", 
      "loss", 
      "effect", 
      "presence", 
      "hope", 
      "concentrate", 
      "recovers", 
      "literature", 
      "addition", 
      "rapid evolution", 
      "success", 
      "decades", 
      "future", 
      "evolution"
    ], 
    "name": "Complement and the atypical hemolytic uremic syndrome in children", 
    "pagination": "1957-1972", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019980601"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00467-008-0872-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18594873"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00467-008-0872-4", 
      "https://app.dimensions.ai/details/publication/pub.1019980601"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_475.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00467-008-0872-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00467-008-0872-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00467-008-0872-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00467-008-0872-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00467-008-0872-4'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      21 PREDICATES      123 URIs      106 LITERALS      12 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00467-008-0872-4 schema:about N2503ac8babc041e38fe554abb2ba2778
2 N5a07952444c8499397784d0b04d94b7a
3 N9b4a7330ed72402aaee18921da8111f9
4 Nbd868abf94994411a0d359335c5052fd
5 Nf4e53a52de934ea996a8a64e216df2a1
6 anzsrc-for:11
7 anzsrc-for:1103
8 schema:author N499964bde2704926905f14adf727bcb7
9 schema:citation sg:pub.10.1007/s00467-003-1192-3
10 sg:pub.10.1007/s00467-003-1371-2
11 sg:pub.10.1007/s00467-004-1526-9
12 sg:pub.10.1007/s00467-006-0237-9
13 sg:pub.10.1007/s00467-007-0438-x
14 sg:pub.10.1007/s00467-007-0540-0
15 sg:pub.10.1007/s00467-008-0964-1
16 sg:pub.10.1007/s004670100609
17 sg:pub.10.1038/ncpneph0465
18 schema:datePublished 2008-11-01
19 schema:datePublishedReg 2008-11-01
20 schema:description Over the past decade, atypical hemolytic uremic syndrome (aHUS) has been demonstrated to be a disorder of the regulation of the complement alternative pathway. Among approximately 200 children with the disease, reported in the literature, 50% had mutations of the complement regulatory proteins factor H, membrane cofactor protein (MCP) or factor I. Mutations in factor B and C3 have also been reported recently. In addition, 10% of children have factor H dysfunction due to anti-factor H antibodies. Early age at onset appears as characteristic of factor H and factor I mutated patients, while MCP-associated HUS is not observed before age 1 year. Low C3 level may occur in patients with factor H and factor I mutation, while C3 level is generally normal in MCP-mutated patients. Normal plasma factor H and factor I levels do not preclude the presence of a mutation in these genes. The worst prognosis is for factor H-mutated patients, as 60% die or reach end-stage renal disease (ESRD) within the first year after onset of the disease. Patients with mutations in MCP have a relapsing course, but no patient has ever reached ESRD in the first year of the disease. Half of the patients with factor I mutations have a rapid evolution to ESRD, but half recover. Early intensive plasmatherapy appears to have a beneficial effect, except in MCP-mutated patients. There is a high risk of graft loss for HUS recurrence or thrombosis in all groups except the MCP-mutated group. Recent success of liver–kidney transplantation combined with plasmatherapy opens this option for patients with mutations of factors synthesized in the liver. New therapies such as factor H concentrate or complement inhibitors offer hope for the future.
21 schema:genre article
22 schema:isAccessibleForFree true
23 schema:isPartOf N6bb36214b7dc42b69dc7ce6368a8da5e
24 N8fe074e2b3704ed0b951930fdf93c2e7
25 sg:journal.1097267
26 schema:keywords C3
27 C3 levels
28 H antibodies
29 HUS
30 HUS recurrence
31 I levels
32 I mutations
33 I. Mutations
34 addition
35 age
36 age 1 year
37 alternative pathway
38 anti-factor H antibodies
39 antibodies
40 atypical hemolytic uremic syndrome
41 beneficial effects
42 children
43 cofactor protein
44 complement
45 complement alternative pathway
46 complement inhibitors
47 complement regulatory protein factor H
48 concentrate
49 course
50 decades
51 disease
52 disorders
53 dysfunction
54 early age
55 effect
56 end-stage renal disease
57 evolution
58 factor B
59 factor H
60 factor H dysfunction
61 factor I
62 factor I levels
63 factor I mutation
64 factors
65 first year
66 future
67 genes
68 graft loss
69 group
70 half
71 hemolytic uremic syndrome
72 high risk
73 hope
74 inhibitors
75 levels
76 literature
77 liver
78 liver-kidney transplantation
79 loss
80 low C3 levels
81 membrane cofactor protein
82 mutations
83 new therapies
84 onset
85 options
86 past decade
87 pathway
88 patients
89 plasmatherapy
90 presence
91 prognosis
92 protein
93 rapid evolution
94 recent success
95 recovers
96 recurrence
97 regulation
98 regulatory protein factor H
99 relapsing course
100 renal disease
101 risk
102 success
103 syndrome
104 therapy
105 thrombosis
106 transplantation
107 uremic syndrome
108 worse prognosis
109 years
110 schema:name Complement and the atypical hemolytic uremic syndrome in children
111 schema:pagination 1957-1972
112 schema:productId N0f28e08089dd45568fcd1fd537c2d565
113 Nc0e75285db7e4f68a26c9afba10b0c33
114 Nc0f11027367e4360a0dfb0d9233761ce
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019980601
116 https://doi.org/10.1007/s00467-008-0872-4
117 schema:sdDatePublished 2022-09-02T15:52
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher N0f0d6066a8b24d6e8a35cc24820b0595
120 schema:url https://doi.org/10.1007/s00467-008-0872-4
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N0f0d6066a8b24d6e8a35cc24820b0595 schema:name Springer Nature - SN SciGraph project
125 rdf:type schema:Organization
126 N0f28e08089dd45568fcd1fd537c2d565 schema:name pubmed_id
127 schema:value 18594873
128 rdf:type schema:PropertyValue
129 N2503ac8babc041e38fe554abb2ba2778 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Complement System Proteins
131 rdf:type schema:DefinedTerm
132 N499964bde2704926905f14adf727bcb7 rdf:first sg:person.01274311230.19
133 rdf:rest N74eace37f7d544f7a2aae752c05244e3
134 N5a07952444c8499397784d0b04d94b7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N6bb36214b7dc42b69dc7ce6368a8da5e schema:volumeNumber 23
138 rdf:type schema:PublicationVolume
139 N74eace37f7d544f7a2aae752c05244e3 rdf:first sg:person.0737342403.33
140 rdf:rest Nca4ee5cabf5446b98b939fd02b8e7494
141 N8fe074e2b3704ed0b951930fdf93c2e7 schema:issueNumber 11
142 rdf:type schema:PublicationIssue
143 N9b4a7330ed72402aaee18921da8111f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Child
145 rdf:type schema:DefinedTerm
146 Nbd868abf94994411a0d359335c5052fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Hemolytic-Uremic Syndrome
148 rdf:type schema:DefinedTerm
149 Nc0e75285db7e4f68a26c9afba10b0c33 schema:name dimensions_id
150 schema:value pub.1019980601
151 rdf:type schema:PropertyValue
152 Nc0f11027367e4360a0dfb0d9233761ce schema:name doi
153 schema:value 10.1007/s00467-008-0872-4
154 rdf:type schema:PropertyValue
155 Nca4ee5cabf5446b98b939fd02b8e7494 rdf:first sg:person.0776460004.20
156 rdf:rest rdf:nil
157 Nf4e53a52de934ea996a8a64e216df2a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Education, Medical, Continuing
159 rdf:type schema:DefinedTerm
160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
161 schema:name Medical and Health Sciences
162 rdf:type schema:DefinedTerm
163 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
164 schema:name Clinical Sciences
165 rdf:type schema:DefinedTerm
166 sg:journal.1097267 schema:issn 0931-041X
167 1432-198X
168 schema:name Pediatric Nephrology
169 schema:publisher Springer Nature
170 rdf:type schema:Periodical
171 sg:person.01274311230.19 schema:affiliation grid-institutes:grid.413235.2
172 schema:familyName Loirat
173 schema:givenName Chantal
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274311230.19
175 rdf:type schema:Person
176 sg:person.0737342403.33 schema:affiliation grid-institutes:grid.4527.4
177 schema:familyName Noris
178 schema:givenName Marina
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737342403.33
180 rdf:type schema:Person
181 sg:person.0776460004.20 schema:affiliation grid-institutes:grid.414093.b
182 schema:familyName Fremeaux-Bacchi
183 schema:givenName Véronique
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776460004.20
185 rdf:type schema:Person
186 sg:pub.10.1007/s00467-003-1192-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013508805
187 https://doi.org/10.1007/s00467-003-1192-3
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/s00467-003-1371-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031866227
190 https://doi.org/10.1007/s00467-003-1371-2
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/s00467-004-1526-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011641665
193 https://doi.org/10.1007/s00467-004-1526-9
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s00467-006-0237-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048718146
196 https://doi.org/10.1007/s00467-006-0237-9
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s00467-007-0438-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1024083847
199 https://doi.org/10.1007/s00467-007-0438-x
200 rdf:type schema:CreativeWork
201 sg:pub.10.1007/s00467-007-0540-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019453541
202 https://doi.org/10.1007/s00467-007-0540-0
203 rdf:type schema:CreativeWork
204 sg:pub.10.1007/s00467-008-0964-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034552033
205 https://doi.org/10.1007/s00467-008-0964-1
206 rdf:type schema:CreativeWork
207 sg:pub.10.1007/s004670100609 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038978190
208 https://doi.org/10.1007/s004670100609
209 rdf:type schema:CreativeWork
210 sg:pub.10.1038/ncpneph0465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018873317
211 https://doi.org/10.1038/ncpneph0465
212 rdf:type schema:CreativeWork
213 grid-institutes:grid.413235.2 schema:alternateName Service de Néphrologie, Hôpital Robert Debré, 48 Boulevard Sérurier, 75019, Paris, France
214 schema:name Assistance Publique - Hôpitaux de Paris, Université Paris 7, Hôpital Robert Debré, Pediatric Nephrology, Paris, France
215 Service de Néphrologie, Hôpital Robert Debré, 48 Boulevard Sérurier, 75019, Paris, France
216 rdf:type schema:Organization
217 grid-institutes:grid.414093.b schema:alternateName Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Biological Immunology Department, Paris, France
218 schema:name Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Biological Immunology Department, Paris, France
219 rdf:type schema:Organization
220 grid-institutes:grid.4527.4 schema:alternateName Clinical Research Center for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Ranica, Italy
221 schema:name Clinical Research Center for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Ranica, Italy
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...